Makhpal Sarmykova

Makhpal Sarmykova

Auto-generated profile, based on publicly available information

Makhpal Sarmykova

Research Institute for Biological Safety Problems, Gvardeisky settlement, Republic of Kazakhstan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DBDina Bugybayeva
Dina Bugybayeva
SRSholpan Ryskeldinova
Sholpan Ryskeldinova
NZNadezhda Zinina
Nadezhda Zinina
MSMakhpal Sarmykova
Makhpal Sarmykova
NANurika Narynbekovna Assanzhanova
Nurika Narynbekovna Assanzhanova
KTKaissar Tabynov
Kaissar Tabynov
In this paper, we first used recombinant influenza viral vector (rIVV) subtype H5N1 expressing from the open reading frame of NS1 80 and NS1 124 amino acids of Brucella outer membrane proteins (Omp) 16 and 19, ribosomal L7/L12, and Cu‐Zn superoxide dismutase (SOD) proteins to develop a human brucellosis vaccine. We made 18 combinations of IVVs in mono‐, bi‐, and tetravalent vaccine formulations and tested them on mice to select the safest and most effective vaccine samples. Then, the most effective vaccine candidates were further tested on guinea pigs. Safety of the rIVV‐based vaccine candidate was evaluated by a mouse weight‐gain test. Mice and guinea pigs were challenged with the virulent strain B. melitensis 16M. The protective effect of the rIVV‐based vaccine candidate was assessed by quantitation of Brucella colonization in tissues and organs of challenged animals. All vaccine formulations were safe in mice. Tested vaccine formulations, as well as the commercial B. melitensis Rev.1 vaccine, have been found to protect mice from B. melitensis 16M infection within the range of 1.6 to 2.97 log10 units (P < 0.05). Tetravalent vaccine formulations from the position of NS1 80 amino acids (0.2 ± 0.4), as well as the commercial B. melitensis Rev.1 vaccine (1.2 ± 2.6), have been found to protect guinea pigs from B. melitensis 16M infection at a significant level (P < 0.05). Thus, tetravalent vaccine formulation Flu‐NS1‐80‐Omp16+Flu‐NS1‐80‐L7/L12+Flu‐NS1‐80‐Omp19+Flu‐NS1‐80‐SOD was chosen as a potential vaccine candidate for further development of an effective human vaccine against brucellosis. These results show a promising future for the development of a safe human vaccine against brucellosis based on rIVVs.

1 March 2019 in Acta Tropica
Verified
Journal Article
Closed access
NSNazym Syrym
Nazym Syrym
BYBolat A. Yespembetov
Bolat A. Yespembetov
MSMakhpal K. Sarmykova
Makhpal K. Sarmykova
GKGulshat M. Konbayeva
Gulshat M. Konbayeva
ZKZhumagali Khoshemetov
Zhumagali Khoshemetov
SSSarsenbek T. Siyabekov
Sarsenbek T. Siyabekov

8 June 2019 in Tropical Animal Health and Production
Verified
Journal Article
Closed access
PDF file
BYBolat A. Yespembetov
Bolat A. Yespembetov
NSNazym Syrym
Nazym Syrym
NZNadezhda N. Zinina
Nadezhda N. Zinina
MSMakhpal K. Sarmykova
Makhpal K. Sarmykova
GKGulshat M. Konbayeva
Gulshat M. Konbayeva
SSSarsenbek T. Siyabekov
Sarsenbek T. Siyabekov

25 November 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
BYBolat Yespembetov
Bolat Yespembetov
ZKZhumagul Kirkimbayeva
Zhumagul Kirkimbayeva
AAAkbope Abdykalyk
Akbope Abdykalyk
AAAssel Akhmetova
Assel Akhmetova
ASAlexandr Shevtsov
Alexandr Shevtsov
ATAlinur Toleukhan
Alinur Toleukhan
Background/Objectives: Salmonella enterica is a major cause of foodborne infection globally, with poultry acting as an important reservoir. However, data from Central Asia remain limited. This study provides preliminary phenotypic and genomic characterization of S. enterica isolates recovered from poultry farms in southern Kazakhstan, focusing on antimicrobial resistance (AMR), serotypes/sequence types and phylogenetic relationships. Methods: In October 2024, 335 poultry and environmental samples were collected from three regions of southern Kazakhstan using a cross-sectional, detection-focused sampling strategy. Isolation of Salmonella enterica followed enrichment and selective culturing, with confirmation by biochemical assays, slide agglutination serology and real-time PCR. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method and interpreted according to CLSI veterinary breakpoints (VET01/VET08) and CLSI M100 where veterinary criteria were unavailable. Whole-genome sequencing (Illumina) was used for in silico serotyping, MLST, AMR gene detection, plasmid replicon typing and SNP-based phylogenetic reconstruction. Results: Nine S. enterica isolates were confirmed (overall yield 2.7%; 9/335), comprising S. Enteritidis (ST11; n = 4), S. Infantis (ST32; n = 3) and ST68 (n = 2; Choleraesuis/Paratyphi C lineage). All isolates were resistant to ciprofloxacin, and most displayed resistance to ampicillin, gentamicin and trimethoprim-sulfamethoxazole. Plasmid-associated AMR determinants, including blaTEM-116, tet(A), sul1 and dfrA14, were frequently identified on IncF-type replicons. Phylogenetic analysis revealed that the isolates clustered with previously described Eurasian poultry-associated lineages. Conclusions: In this small, exploratory sample from poultry farms in southern Kazakhstan, all recovered S. enterica isolates were multidrug-resistant, with universal fluoroquinolone resistance and frequent plasmid-borne AMR genes. These preliminary findings provide baseline genomic evidence and highlight the need for broader, harmonized AMR surveillance in the regional poultry sector.

6 September 2025 in Veterinary World
Verified
Journal Article
Open access
ANAinur Nurpeisova
Ainur Nurpeisova
ZAZhandos Abay
Zhandos Abay
MKMarkhabat Kassenov
Markhabat Kassenov
NSNazym Syrym
Nazym Syrym
SSSandugash Sadikaliyeva
Sandugash Sadikaliyeva
KSKamshat Shorayeva
Kamshat Shorayeva
Background and Aim: Bovine tuberculosis (bTB), caused by Mycobacterium bovis, remains a significant zoonotic and eco­nomic threat globally. Despite the long-standing use of the Bacillus Calmette-Guérin (BCG) vaccine, its inconsistent efficacy and interference with surveillance tests underscore the need for alternative approaches. This study evaluated the safety, immunogenicity, and protective efficacy of a novel influenza vector-based vaccine expressing M. bovis antigens ESAT-6 and TB10.4, formulated with or without an adjuvant. Materials and Methods: Recombinant influenza A viruses expressing ESAT-6 and TB10.4 were constructed using reverse genetics and incorporated into vaccine formulations. Guinea pigs and calves were immunized with adjuvanted and non-adjuvanted formulations, followed by challenge with a virulent M. bovis strain. Safety was assessed through clinical observation and histopathology. Immune responses were monitored using interferon-gamma (IFNγ) enzyme-linked immu­nosorbent assay, and protection was evaluated through organ damage indices, bacterial load, and survival rates over a 12-month period. Results: Both formulations were safe and well-tolerated in guinea pigs and calves, with no adverse clinical signs. The non-adjuvanted vaccine induced the highest and most sustained IFNγ response, peaking between 2 and 5 months post-vac­cination. In guinea pigs, the protection index reached +0.60 lg in the non-adjuvanted group versus +0.2 lg in the adjuvanted group. In calves, lung bacterial load was reduced to 1.83–1.93 lg colony-forming unit (CFU) in vaccinated animals compared with 5.8 lg CFU in unvaccinated controls. Histopathological examination confirmed minimal tissue damage in the vaccinated groups. Both vaccine formulations demonstrated protective efficacy equivalent to or better than BCG, with the non-adju­vanted version showing superior performance. Conclusion: This novel influenza vector-based vaccine expressing ESAT-6 and TB10.4 antigens elicits strong, long-lasting cellular immunity and provides significant protection against M. bovis infection in guinea pigs and calves. The adjuvant-free formulation demonstrated higher immunogenicity, simplified production, and minimal adverse reactions, positioning it as a promising alternative to BCG for bTB control in livestock. Keywords: Bovine tuberculosis, calves, ESAT-6, guinea pigs, interferon-gamma, influenza vector, Mycobacterium bovis, protective efficacy, TB10.4, vaccine.

25 June 2023 in Ġylym ža̋ne bìlìm
Verified
Journal Article
Closed access
МСМахпал Сармыкова
Махпал Сармыкова
ЕАЕспембетов Б. А.
Еспембетов Б. А.
СНСырым Н
Сырым Н
АДАлиханов К. Д.
Алиханов К. Д.
САСамбетпаев А.а.
Самбетпаев А.а.